Establishment and Characterization of RMS Cell Lines

Ba/F3 TEL-FGFR4, a murine hematopoietic cell line that expresses a constitutively active FGFR4 kinase domain [19 (link)], was cultured in RPMI-1640 medium supplemented with 10% fetal bovine serum (FBS), 2 mM L-glutamine, 1% penicillin/streptomycin, and 1.5 ug/mL puromycin. RMS559 is a FN RMS cell line with an FGFR4^V550L activating mutation; RH4 and SCMC are FP RMS cell lines with FGFR4 overexpression; and 7250 is a normal human fibroblast cell line. These cell lines were grown in DMEM medium supplemented with 10% FBS, 2 mM L-glutamine, and 1% penicillin/streptomycin. All cell lines were STR profiled and negative for mycoplasma. Futibatinib was obtained through a Cooperative Research and Development Agreement (CRADA) with Taiho Oncology (Princeton, NJ, USA). Irinotecan (752903, Pfizer, New York, NY, USA) and Vincristine (030906, Pfizer) were obtained through the NIH Division of Veterinary Resources Pharmacy.